Clinical Trials Browser

Phase 1/2 × atezolizumab × Thoracic × Clear all

NCT06287775 2026-04-13

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT07227597 2026-04-13

MK-6070-003

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT07407933 2026-04-09

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Lung Diseases, Thoracic Neoplasms, Small Cell Lung Carcinoma

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Phase 1/2 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06362252 2026-02-06

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase 1/2 Recruiting

Extensive Stage-small Cell Lung Cancer

NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04691817 2026-01-07

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05703971 2025-10-16

Acclaim-3

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04101357 2025-03-18

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Phase 1/2 Terminated

54 enrolled 30 charts

Small Cell Lung Carcinoma

NCT04440735 2025-01-09

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06110572 2024-06-20

TESSERACT

Phase 1/2 Recruiting

Lung Neoplasms

NCT05765084 2024-05-16

Immuno-MESODEC

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Wilms Tumor

NCT05240131 2024-04-12

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04487756 2024-04-03

VENEZO-LUNG

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma

NCT04253145 2023-11-18

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Phase 1/2 Unknown

Small Cell Lung Carcinoma

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT03138889 2023-03-10

PROPEL

Phase 1/2 Terminated

162 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03023423 2019-11-20

DARZALEX

Phase 1/2 Completed

100 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02630186 2019-07-05

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Phase 1/2 Terminated

3 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02748889 2018-07-02

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 8 charts

Lung Neoplasms, Small Cell Lung Carcinoma